Back to Journals » Therapeutics and Clinical Risk Management » Volume 1 » Issue 3

Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome

Authors Guido Mannaioni, Roberto Baronti, Flavio Moroni

Published 15 October 2005 Volume 2005:1(3) Pages 225—229

Guido Mannaioni, Roberto Baronti, Flavio Moroni

Department of Preclinical and Clinical Pharmacology University of Florence, Florence, Italy

Background: Neuroleptic malignant syndrome (NMS) is a rare side effect of antipsychotic therapy characterized by fever, muscular rigidity, altered mental status, increased level of serum creatinine phosphokinase, and increased number of white blood cells. The mortality rate of patients with NMS remains elevated.

Methods: We examined the clinical records of patients diagnosed with severe NMS admitted to the Clinical Toxicology Unit, Florence University Hospital, between 1990 and 2004.

Results: Eight patients presented with this neurological disorder. All were treated with supportive therapy, which included dantrolene, levodopa/benserazide, benzodiazepines, metamizole and/or paracetamol, and antibiotics. Five survived and three died. Of the three deceased, two had large hemorrhages in the gastrointestinal tract, and one had massive liver damage and diffuse hemorrhages throughout the body.

Conclusion: Our results suggest that gastrointestinal bleeding is a frequent cause of death in NMS patients. Bleeding may occur as a consequence of commonly accepted medical treatments (especially the use of cyclooxygenase inhibitors as antipyretic agents) and NMS-induced changes in blood coagulation status. To increase the survival rate of these patients, it is necessary to avoid using drugs that may facilitate gastrointestinal lesions and to utilize procedures known to decrease the risk of bleeding.

Keywords: neuroleptic malignant syndrome, fever, gastrointestinal bleeding

Download Article [PDF] 

Readers of this article also read:

Lifestyle changes as a treatment of gastroesophageal reflux disease: a survey of general practitioners in North Queensland, Australia

Madeleine Nowak, Petra Büttner, Beverly Raasch, Kym Daniell, Cindy McCutchan, Simone Harrison

Therapeutics and Clinical Risk Management 2005, 1:219-224

Published Date: 15 October 2005

Absence of the toll-like receptor 4 gene polymorphisms Asp299Gly and Thr399Ile in Singaporean Chinese

Xiao Hui Liang, Wai Cheung, Chew Kiat Heng, De-Yun Wang

Therapeutics and Clinical Risk Management 2005, 1:243-246

Published Date: 15 October 2005

A review of studies of adherence with antihypertensive drugs using prescription databases

Nicola Fitz-Simon, Kathleen Bennett, John Feely

Therapeutics and Clinical Risk Management 2005, 1:93-106

Published Date: 15 July 2005

Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy

Charity D Scripture, William D Figg, Alex Sparreboom

Therapeutics and Clinical Risk Management 2005, 1:107-114

Published Date: 15 July 2005

Renal replacement therapy in the intensive care unit

Neesh Pannu, RT Noel Gibney

Therapeutics and Clinical Risk Management 2005, 1:141-150

Published Date: 15 July 2005

Clinical implications of changes in hepatic drug metabolism in older people

Sarah N Hilmer, Gillian M Shenfield, David G Le Couteur

Therapeutics and Clinical Risk Management 2005, 1:151-156

Published Date: 15 July 2005

Editorial || FREE PAPER ||

Garry Walsh

Therapeutics and Clinical Risk Management 2005, 1:1-1

Published Date: 15 April 2005